Abstract-The enkephalin-inactivating enzymes in rat vas deferens were studied by using the relatively specific inhibitor of each enzyme.
deferens
and striatal membranes of guinea-pig brain, which had been investigated previously, contained three distinct enkephalin-hydrolyzing peptidases. Additionally, the enkephalin-hydrolyzing aminopeptidase, endopeptidase-24.11 and peptidyl dipeptidase A in rat vas deferens were found to be inhibited maximally with 1 IN of amastatin, 1 iiM of phosphoramidon and 1 ,IM of captopril, respectively. In contrast to these three enzymes, both L-tyrosyl-L-tyrosine-sensitive dipeptidyl aminopeptidase and D-phenylalanine-sensitive carboxypeptidase were suggested not to be involved significantly in the inactivation of exogenously given enkephalin in rat vas deferens.
The characteristics of the enkephalin-degradative enzymes in rat vas deferens were discussed in terms of their similarities to and differences from those in the other preparations.
Three enzymes, both bestatin and amastatin-sensitive aminopeptidase, both thiorphan and phosphoramidon-sensitive endopeptidase-24. 11 ("enkephalinase", EC 3.4.24.11), and captopril-sensitive peptidyl dipeptidase A (angiotensin I converting enzyme, kininase II, peptidyldipeptide hy drolase, EC 3.4.15.1), have been shown to play important roles in the inactivation of exogenously given enkephalin in two in vitro isolated preparations, guinea-pig ileum (1) and mouse vas deferens (2) . Additionally, these three enzymes have been indicated to be located very close to opioid receptors (1, 2) . Moreover, enkephalin has been shown to be exclusively inactivated by these three peptidases, since enkephalin remains intact almost totally after it is incubated with either ileal or striatal membrane fractions of guinea pig for 60 min at 37'C in the presence of three peptidase inhibitors, amastatin, thior phan and captopril, although free tyrosine and the Tyr-Gly-Gly fragment are produced when the incubation mixture does not contain the peptidase inhibitor (3).
On the other hand, the structure of phos phoramidon-sensitive endopeptidase-24.1 1 in the kidney has been reported to be slightly different from either that in the intestine (4) or that in the brain (5) . Additionally, the lung and brain peptidyl dipeptidases have been shown to differ markedly in their substrate preference with the lung enzyme, failing to degrade substance K, while the brain enzyme displays similar activity toward substance K and substance P (6) . Moreover, the inhibitory potency of /9-endorphin has been shown to be significantly enhanced by the pretreatment of the mouse vas deferens with three peptidase inhibitors, amastatin, captopril and phosphoramidon, while it is not augmented in both guinea-pig ileum and rat vas deferens by the same pretreatment (7) . These four reports suggest that the structure or the function of a particular peptidase in one preparation or tissue may not always be the same as that in the other.
In the present investigation, therefore, the effect of peptidase inhibitor on the potency of [Met5]-enkephalin in rat vas deferens was examined in order to e'ucidate whether or not the enkephalin-hydrolyzing peptidase in rat vas deferens had the same characteristics as that in guinea-pig ileum (1) or mouse vas deferens (2).
Materials and Methods

Chemicals:
Gifts of compounds which were gratefully received were amastatin and phosphoramidon from Dr. In vitro isolated preparations: Male Wistar rats weighing 300-500 g were used for this study. The vasa deferentia from rats were prepared and set up for electrical stimulation as described previously (8) . The % inhibition of the stimulated muscle twitch produced by [Met5]-enkephalin was plotted against the log concentration of the opioid to estimate the IC50 (concentration of the opioid to produce 50% inhibition of the twitch). When the effect of peptidase inhibitors on the IC50 value of [Met5]-enkephalin was studied, they were given at least ten minutes before the enkephalin administration. The % difference shown in the table was calculated as described previously (2) . The significance of % differences between IC50 values of two adjacent groups shown in the table was determined by the paired Student's t-test.
Results
The control experiment: The IC50 value of [Met5]-enkephalin was repeatedly estimated for five times in six preparations of rat vas deferens in order to examine the stabi ity of the response of the preparation to an opioid during the usual experimental period, since it has been shown that the sensitivity to an opioid of rabbit vas deferens was significantly increased with the passage of time (9), while that of guinea-pig ileum was not significantly changed during the usual experimental period (1) . The IC50 values of [Met5] enkephalin estimated initially and secondarily were significantly higher than those estimated secondarily and thirdly, respectively ( Table  1) . On the other hand, the IC50 values estimated thirdly and fourthly were not sig nificantly different from those estimated fourthly and fifthly, respectively (Table 1) . Since the increased sensitivity of the pre paration to an opioid during the per od from the initial to the third determination of the IC50 value ( in the presence of three peptidase inhibitors were also decreased during the period from their initial to third determinations (Table  1) , indicating the negative involvement of the peptidases in the increased sensitivity of the preparation to an opioid during the early phase of the experiment.
Since the results obtained in both the absence and the presence of the peptidase inhibitors showed that the response of the preparation to an opioid was not significantly changed during the period from the third to the fifth estimation of the IC50 value, the following experiments on the effect of the peptidase inhibitor on the potency of [Met5]-enkephalin in rat vas deferens were carried out during the equivalent period from the third to the fifth estimation of the IC50 value.
Enhanced :,The mixture of three peptidase inhibitors, amastatin, captopril and phosphoramidon, was given 10 min before the enkephalin administration at the final concentration of 1 fiM each. ***P<0.01. ileal and striatal membrane fractions of guinea-pig (3) . Therefore, the presence of the enzyme with low enkephalin-hydrolyzing activity was sometimes difficult to detect when the residual enzyme with high enkephalin-hydrolyzing activity was not inhibited (3) . Then, when the enkephalin hydrolyzing ability of a particular enzyme among three enzymes was examined, the residual two enzymes were inhibited in advance in the present study.
Initially, the effect of amastatin, an amino peptidase inhibitor, on the inhibitory potency of [Met5]-enkephalin in the rat vas deferens pretreated with two peptidase inhibitors, phosphoramidon and captopril, at the final concentration of 1 /iM each was examined. The IC50 value of enkephalin in the presence of 1 ,uM of amastatin was not significantly different from that of 2 pM of amastatin, but significantly lower than that of 0.1 uM of amastatin (Table 2 ). This implied that the enkephalin-hydrolyzing aminopeptidase in rat vas deferens was inhibited maximally with amastatin at the final concentration of 1 ,uM, being consistent with the previous findings obtained with guinea-pig ileum (1) and mouse vas deferens (2). However, Corbett et al. (10) and McKnight et al. (11) have suggested that the susceptibility to bestatin, another aminopeptidase inhibitor, of the enkephalin-hydrolyzing aminopeptidase in rat vas deferens was lower than that in guinea-pig ileum or mouse vas deferens, since they had used 30 pcM of bestatin in rat vas deferens but 10 uM of bestatin in both guinea-pig ileum and mouse vas deferens to inhibit the enkephalin-hydrolyzing amino peptidase.
In order to confirm the present observation, therefore, the effect of the increasing doses of amastatin on the electrically-evoked contractions of the rat vas deferens pretreated with both captopril and phosphoramidon was examined in the presence of [Met5]-enkephalin in the organ bath. Amastatin at the final concentration of 0.1 /cM significantly enhanced the enkephalin induced inhibition of the contractions of the rat vas deferens pretreated with both captopril and phosphoramidon (Fig. 1) . Additionally, the enhanced inhibition produced by 0 .1 ,cM of amastatin was further augmented by increasing the dose of amastatin to 1 /iM (Fig. 1) . However, the inhibition induced by 1 /IM of amastatin was not further enhanced by increasing the dose of amastatin to 10 iiM (Fig. 1) . The inhibition produced by the administration of both [Met5]-enkephalin and amastatin was completely reversed by 1 ,uM of naloxone, a specific opioid antagonist (Fig .  1) . The result suggested that the enkephalin hydrolyzing aminopeptidase was inhibited maximally with amastatin at the final concen tration of 1 /iM, and the amastatin-induced inhibition of the contractions of the rat vas deferens in the presence of enkephalin was caused by the increased amount of an opioid in the vicinity of receptors .
Secondarily, the effect of phosphoramidon, an inhibitor of endopeptidase-24.11, on the inhibitory potency of [Met5]-enkephalin in the rat vas deferens pretreated with two peptidase inhibitors, amastatin and captopril, at the final concentration of 1 tiM each was estimated. The IC50 value of enkephalin in the presence of 1 /-,M of phosphoramiclon was not significantly different from that of 2 uM of phosphoramidon, but significantly lower than that of 0.1 /iM of phosphoramidon (Table 3 ). This indicated that the enkephalin hydrolyzing endopeptidase-24.11 in rat vas deferens was inhibited maximally with phos phoramidon at the final concentration of 1 riM, being consistent with the previous results obtained with guinea-pig ileum (1 ), mouse vas deferens (2), pig caudate synaptic membranes (12) and purified endopeptidase 24.11 from pig kidney (13) .
Thirdly, the effect of captopril, an inhibitor of peptidyl dipeptidase A, on the inhibitory potency of [Met5]-enkephalin in the rat vas deferens pretreated with two peptidase inhibitors, amastatin, and phosphoramidon , at the final concentration of 1 ;€M each was examined. The IC50 value of enkephalin in the presence of 1 ,uM of captopril was not significantly different from that of 2 -tM of captopril, but significantly lower than that of 0.1 ,uM of captopril (Table 4 ). This suggested that the enkephalin-hydrolyzing peptidyl dipeptidase A in rat vas deferens was inhibited maximally with captopril at the final concen tration of 1 tiM, being consistent with the previous results obtained with guinea-pig ileum (1 ), mouse vas deferens (2) and a membrane preparation from the electric organ of Torpedo marmorata (14) .
Finally, the effect of either L-tyrosyl-L tyrosine, an inhibitor of an aminoterminal directed dipeptidylpeptidase and captopril, at the final concentration of 1 uM each, in mouse vas deferens has been shown to be approximately three-fold higher than that in guinea-pig ileum, but two to three-fold lower than that in rat vas deferens (7) . Additionally, the mixture of these three peptidase inhibitors has been shown not to enhance significantly the inhibitory potency of 9-endorphin in both guinea-pig ileum and rat vas deferens but augment significantly the potency of 3-endorphin in mouse vas deferens (7) .
In conclusion, the rat vas deferens, like the other three preparations, guinea-pig ileum (1), mouse vas deferens (2) and striatal mem branes of guinea-pig brain (3) , is shown to contain three distinct enkephalin-inactivating enzymes. Additionally, the susceptibility of the enkephalin-hydrolyzing enzymes to in hibitors in rat vas deferens is found to be similar to that in both guinea-pig ileum (1) and mouse vas deferens (2), although the peptidases in rat vas deferens have been shown to be different from those in mouse vas deferens in terms of the ability of the l9 endorphin hydrolysis (7) .
